41
www.rti.org RTI International is a registered trademark and a trade name of Research Triangle Institute. The Association Between Motivational Subtypes and Medical Cannabis Consumption: A 30-Day Diary Study The Cannabis Science and Policy Summit Scott P. Novak, Ph.D. Senior Research Scientist t Americas Regional Meeting of the International Society for the Study of Drug Policy on Cannabis Policy New York, New York April 18, 2016

Cannabis Science & Policy Summit - Day 2 - Novak

Embed Size (px)

Citation preview

Page 1: Cannabis Science & Policy Summit - Day 2 - Novak

www.rti.orgRTI International is a registered trademark and a trade name of Research Triangle Institute.

The Association Between Motivational Subtypes and Medical Cannabis Consumption: A 30-Day Diary Study

The Cannabis Science and Policy Summit

Scott P. Novak, Ph.D.

Senior Research Scientist

tAmericas Regional Meeting of the International Society for the Study of Drug Policy on Cannabis Policy

New York, New York

April 18, 2016

Page 2: Cannabis Science & Policy Summit - Day 2 - Novak

Conflicts of Interest

Dr. Novak has no Financial or Personal Conflicts of Interest; he

supports medicalization of cannabis, but not full-scale legalization

The opinions and interpretation of study findings do not

necessarily reflect those of the funding agencies or RTI

International

Page 3: Cannabis Science & Policy Summit - Day 2 - Novak

Acknowledgements

Funding:

National Institute on Drug Abuse (P.I. Dr. Novak, DA030427)

RTI International Strategic Investment Fund (SIF)

RTI Co-authors:

Gary A. Zarkin, Ph.D. (Economics)

Nick Peiper, Ph.D., MPH (Public Health)

Camille Gourdet, J.D. (Law)

Mark Edlund, M.D., Ph.D. (Medicine/Pain)

Jenny Wiley, Ph.D. (Behavioral Pharmacology)

Olivia Taylor, MS (Communication Science)

Georgiy Bobashev, Ph.D. (Computational Science)

Elizabeth Ball, BA (Social Psychology)

Consultant:

Diana Fishbein, Ph.D. (Neuroscience, Penn State University)

Page 4: Cannabis Science & Policy Summit - Day 2 - Novak

Today’s Talk: Overview

Identify the patterns of consumption involving commonly used

cannabis products (e.g., smoked, edibles) in 30 day window

among medical cannabis patients

Page 5: Cannabis Science & Policy Summit - Day 2 - Novak

Today’s Talk: Overview

Identify the patterns of consumption involving commonly used

cannabis products (e.g., smoked, edibles) in 30 day window

among medical cannabis patients

Examine the association between consumption patterns and

individual differences in delayed discounting, discretionary

income, diversion, and disease status

Page 6: Cannabis Science & Policy Summit - Day 2 - Novak

Today’s Talk: Overview

Identify the patterns of consumption involving commonly used

cannabis products (e.g., smoked, edibles) in 30 day window

among medical cannabis patients

Examine the association between consumption patterns and

individual differences in delayed discounting, discretionary

income, peer influence, novelty seeking, and medical need

Discuss the policy-implications of product regulation for

promoting public health outcomes in the United States

Page 7: Cannabis Science & Policy Summit - Day 2 - Novak

Translational Scientific Lens: Bridging Science and Policy

Population

Science

Laboratory

Science

Public

Clinical

Policy

Step 1: Identify number of different

subtypes (classes) of consumption

Practices

Step 2: Estimate number of

persons in each type (classes)

Step 3: Link consumption practices

with adverse mental and physical

health outcomes using animal

models of self-administration

Step 4: Connect consumption

practices with physiological and

psychological outcomes

Step 5: Using computer simulation

modeling, project the health

outcomes based on known

population parameters (validation)

Step 6: Extrapolate the impact of

different policies to expand or

restrict different

products/consumption practices

Page 8: Cannabis Science & Policy Summit - Day 2 - Novak

Translational Scientific Lens: Bridging Science and Policy

Population

Science

Laboratory

Science

Public

Clinical

Policy

Step 1: Identify number of different

subtypes (classes) of consumption

Practices

Step 2: Estimate number of

persons in each type (classes)

Step 3: Link consumption practices

with adverse mental and physical

health outcomes using animal

models of self-administration

Step 4: Connect consumption

practices with physiological and

psychological outcomes

Step 5: Using computer simulation

modeling, project the health

outcomes based on known

population parameters (validation)

Step 6: Extrapolate the impact of

different policies to expand or

restrict different

products/consumption practices

Page 9: Cannabis Science & Policy Summit - Day 2 - Novak

The Present Study

Medical Cannabis Users recruited in San Francisco, CA (n=50)

Page 10: Cannabis Science & Policy Summit - Day 2 - Novak

The Present Study

Medical Cannabis Users recruited in San Francisco, CA (n=50)

Recruitment flyers placed at local dispensaries in San Francisco

and advertisements placed on Craigslist, Online Cannabis

websites

Page 11: Cannabis Science & Policy Summit - Day 2 - Novak

The Present Study

Medical Cannabis Users recruited in San Francisco, CA (n=50)

Recruitment flyers placed at local dispensaries in San Francisco

and advertisements placed on Craigslist, Online Cannabis

websites

Subjects screened over the phone for age (age 18+) and medical

cannabis condition

Page 12: Cannabis Science & Policy Summit - Day 2 - Novak

The Present Study

Medical Cannabis Users recruited in San Francisco, CA (n=50)

Recruitment flyers placed at local dispensaries in San Francisco

and advertisements placed on Craigslist, Online Cannabis

websites

Subjects screened over the phone for age (age 18+) and medical

cannabis condition

Data collection occurred at RTI office (Sansone/Market), presented

valid driver’s license/state ID and medical ID card for cannabis

Page 13: Cannabis Science & Policy Summit - Day 2 - Novak

The Present Study

Medical Cannabis Users recruited in San Francisco, CA (n=50)

Recruitment flyers placed at local dispensaries in San Francisco

and advertisements placed on Craigslist, Online Cannabis

websites

Subjects screened over the phone for age (age 18+) and medical

cannabis condition

Data collection occurred at RTI office (Sansone/Market), presented

valid driver’s license/state ID and medical ID card for cannabis

Data Collection: May to July of 2015

All procedures and survey items approved by RTI IRB

Page 14: Cannabis Science & Policy Summit - Day 2 - Novak

Intensive Longitudinal Data: Daily Paper Diary

Issued a Daily Diary for

Each Patient

Named Motivation for

Use, Number of times

used, and Product Used

Goal was to identify

peak exposure, average

exposure, minimum

exposure and variability

Page 15: Cannabis Science & Policy Summit - Day 2 - Novak

Medical Cannabis: What’s In it?

Used “off-the-shelf” cannalytics testing kit: Identify 20 or so active

pharmacological agents, including Cannabidiol (CBD) and

Tetrahydocannabidiol (THC)

Page 16: Cannabis Science & Policy Summit - Day 2 - Novak

Sample Descriptive Statistics

Characteristic Percent

Males

Females

72%

28%

White

Black

Hispanic

Asian

Other

50%

15%

18%

12%

5%

18-24

25-39

40-55

55 or older

25%

33%

35%

07%

Employed (F/PT) 85%

Initiated use prior to

marijuana card

96%

Age of First Use <18 90%

Diversion 68%

Public Aid 35%

Page 17: Cannabis Science & Policy Summit - Day 2 - Novak

Common Medical Conditions among Marijuana Patients

15%

20%

5%

4%

15%

17%

22%

2%

41%

Migraine Lower Back HIV/AIDS Cancer G.I. Sleeping Anxiety PTSD

Mental Disorder/Sleep/Anxiety most common conditions, followed by

non-specific pain (lower back)

Page 18: Cannabis Science & Policy Summit - Day 2 - Novak

Identify the patterns of consumption involving commonly used cannabis products

Page 19: Cannabis Science & Policy Summit - Day 2 - Novak

Statistical Methodology

Latent Class Analysis: observed indicators are caused by an

unobserved, or latent variable of interest

Covariation among the observed indicators is expected

Study the patterns of interrelationships among the observed

indicators to understand and characterize the underlying latent

variable

Goal: To group individuals into categories, each one of which

contains individuals who are similar to each other and different from

individuals in other categories

Identify the number of categories and assign each person 1 and only

1 category that best represents their observed data

Use class assignment as predictor or outcome in explanatory

modeling

Page 20: Cannabis Science & Policy Summit - Day 2 - Novak

20

The LCA Model

Observed Continuous (y’s)

or Categorical Items (u’s)

Categorical Latent Class

Variable (c)

Continuous or Categorical

Covariates (x)

C

Y1 Y2 Y3 Yp

X

. . .

Page 21: Cannabis Science & Policy Summit - Day 2 - Novak

21

How is this modeling process conducted?

Run through models imposing different numbers of classes

Estimation via the EM algorithm

– Start with random split of people into classes.

– Reclassify based on a improvement criterion

– Reclassify until the best classification of people is found.

Page 22: Cannabis Science & Policy Summit - Day 2 - Novak

Types of Marijuana

Bud

Vape

Edible

Waxy

Alcohol: little attention to product variability

Tobacco: eCigarattes

Marijuana: New attention to product as 40% of

marijuana sold in Colorado was edible.

Page 23: Cannabis Science & Policy Summit - Day 2 - Novak

Observed variables in each classification

Motivation Product

Therapeutic (Pure) Flower or bud

Euphoric (Pure) Hash

Therapeutic and Euphoric (Mixed) Wax

Oil

Edibles

Topical Cream

Tinctures

Capsules

Page 24: Cannabis Science & Policy Summit - Day 2 - Novak

Latent Classes of Motivations by Product Type

Pure Therapy10%

Pure Euphoria10%

Mixed 55%

Smoked Euphoria25%

Page 25: Cannabis Science & Policy Summit - Day 2 - Novak

Results of Initial LCA

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

Pure Therapy Pure Euphoria Mixed Smoke-Euphoria

Page 26: Cannabis Science & Policy Summit - Day 2 - Novak

Results of Initial LCA: Pure Therapy (10%)

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

Pure Therapy

Edible/Mix

Cream/Med

Pil/Med

Edible/Med

Page 27: Cannabis Science & Policy Summit - Day 2 - Novak

Results of Initial LCA: Pure Euphoria (10%)

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

Pure Euphoria

Edible/Euphoria Smoked/Euphoria

Dab/Euphoria

Page 28: Cannabis Science & Policy Summit - Day 2 - Novak

Results of Initial LCA: Mixed (55%)

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

Mixed

SMK/Mixed

DAB/MixedEdible/Mixed

Page 29: Cannabis Science & Policy Summit - Day 2 - Novak

Results of Initial LCA: Smoked Euphoria (25%)

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

Smoke-Euphoria

Edible/Euphoria

Smoked/Euphoria

Dab/Mixed

Page 30: Cannabis Science & Policy Summit - Day 2 - Novak

Who is in which class?

Page 31: Cannabis Science & Policy Summit - Day 2 - Novak

Characteristics of Latent Classes

Legend: O.R.=Odds Ratio (relative to other 3 classes); Note: adjusted for age and sex; NS=Non-significant at P<.05; All listed coefficients

significant at P<.05

Pure Therapy Pure

Euphoria

Mixed Smoked

Euphoria

Males (vs.

Females)

O.R.=0.79 O.R.=1.6 NS O.R.=1.91

Migraine O.R.=1.59 O.R.=.65 NS NS

Anxiety O.R.=0.65 O.R.=1.43 NS O.R.=1.54

Cancer/COPD NS NS NS O.R.=0.25

Diversion O.R.=0.76 O.R.=1.25 NS O.R.=1.36

Delayed

Discounting

O.R.=1.09 O.R.=0.97 NS O.R.=0.98

Public Aid O.R.=1.5 O.R.=0.75 NS O.R.=0.68

Page 32: Cannabis Science & Policy Summit - Day 2 - Novak

Probability of Consumption by Day of Week

0.6

8

0.4

6

0.5

5

0.4

5

0.6

5

0.7

2

0.8

7

0.6

7

0.5

8

0.5

8

0.4

8

0.6

0.7

8

0.8

8

0.6

7

0.4

5

0.5

9

0.5

0.6

1

0.7

1

0.8

7

0.6

8

0.4

3

0.4

9

0.5

5

0.6

2

0.7

0.8

7

SUN MON TUES W ED THUR FRIDAY SAT

Week 1 Week 2 Week 3 Week 4

Page 33: Cannabis Science & Policy Summit - Day 2 - Novak

Probability of Consumption and Modal Consumption Events

0

1

2

3

4

5

6

7

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

% Use Events/Day

Page 34: Cannabis Science & Policy Summit - Day 2 - Novak

Probability of Consumption Based on Date

0

1

2

3

4

5

6

7

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

% Use Events/Day

Payday

Payday

Payday

Page 35: Cannabis Science & Policy Summit - Day 2 - Novak

The “Payday” effect for Probability of Use each Date

0.75

0.8

0.85

0.9

0.95

1

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

% Use

Payday

Payday

Payday

Page 36: Cannabis Science & Policy Summit - Day 2 - Novak

Key Findings

Very few persons consume medical marijuana for purely medicinal-

type reasons; euphoria/relaxation key part. Possible indirect pain

relief pathways (secondary)

Significant proportion of sample appears to consume via smoked,

despite the adverse health effects.

Edibles comprised about 40% of the user groups, but often mixed in

with other user groups.

Males gravitate more toward euphoric use.

Experienced user groups: nearly all user groups reported initiation

prior to receiving medical card, and onset prior to age 18.

Use linked to weekend, and “Payday Effect”.

Page 37: Cannabis Science & Policy Summit - Day 2 - Novak

Limitations and Offsetting Strengths

LIMITATIONS:

Limited Number of Patients: Limited power for subgroup analysis

Study conducted only in CA: Concerns about generalizability

Self-Report Data: No Urine Drug Screen (UDS) to ensure validity

STRENGTHS:

Intensive Measures of Use: Capture diverse range of usage patterns

Diverse number of products: Ability to identify different consumption practices

Page 38: Cannabis Science & Policy Summit - Day 2 - Novak

Next Steps in Scientific Program

Population

Science

Laboratory

Science

Public

Clinical

Policy

Step 1: Identify number of different

subtypes (classes) of consumption

Practices

Step 2: Estimate number of

persons in each type (classes)

Step 3: Link consumption practices

with adverse mental and physical

health outcomes using animal

models of self-administration

Step 4: Connect consumption

practices with physiological and

psychological outcomes

Step 5: Using computer simulation

modeling, project the health

outcomes based on known

population parameters (validation)

Step 6: Extrapolate the impact of

different policies to expand or

restrict different

products/consumption practices

Page 39: Cannabis Science & Policy Summit - Day 2 - Novak

What are the policy implications?

Page 40: Cannabis Science & Policy Summit - Day 2 - Novak

Policy Implications

REMS: For medications with abuse liability, FDA requires Risk

Evaluation and Mitigation Strategy (REMS) by manufacturers. But,

medical users are every experienced.

TOBACCO Policy: Concerns of how to regulate, as tobacco, alcohol,

gambling, or prescription medicine. Significant number of users that

smoke signifies that tobacco regulatory framework holds merit, but

universal adoption should be cautioned.

RESHEDULING: Potential Scheduling of Cannabis by DEA in 2016?

Page 41: Cannabis Science & Policy Summit - Day 2 - Novak

More Information

Name

Scott Novak, Ph.D.

919-541-7129

[email protected]